摘要
目的探讨德国威伐光联合伐昔洛韦、甲钴胺、加巴喷丁治疗急性期带状疱疹,对于减轻带状疱疹后遗神经痛的疗效及安全性。方法采用随机、双盲、平行对照临床研究,入选急性期带状疱疹患者125例,实验组63例,对照组62例。对照组口服伐昔洛韦片、甲钴胺片、加巴喷丁胶囊,实验组在对照组治疗的基础上,加用威伐光治疗系统,治疗1次/d,30 min/次,连续治疗2周。分析2组的疗效,评估其安全性。结果治疗前2组患者的疼痛强度VAS评分无差异性(P>0.05),治疗后2组疼痛评分均有所下降(P<0.05),并呈现VAS递减的趋势;组间比较,治疗组患者在治疗后几个时间点(治疗后第4、8、16、24周末)VAS评分均比对照组低(P<0.05)。2组均未见明显不良反应。结论威伐光联合伐昔洛韦、甲钴胺、加巴喷丁治疗急性期带状疱疹,对减轻患者后期的神经痛疗效显著,明显优于传统的药物治疗。
Objective To explore the clinical efficacy and safety of the combination treatment of wlRA and Valacyclovir, Methylcobalamin and Gabapentin on acute phase herpes zoster and post-herpetic neuralgia. Methods By using the random, blind and controlled clinical trial method, 125 patients underwent the acute phrase of herpes zoster were adopted in the trail, including the 63 patients in the trail group and 62 patients in the eontrol group. The trail groups received the wIRA treatment in addition to Valacyclovir,Methylcobalamin and Oabapentin treatment,whereas the control group only received the drug treatment. Results PTN was alleviated in both two groups compared with the onset of herpes zoster, there was statistics significance（P〈0. 05） 4 weeks later （trail group 4.61 ± 0.35 VS. control 98± 0.68）, 8weeks later（trail group 3.78 ± 0.52 VS. control 4.84 ± 0.47）, 16 weeks later（trail group 2. 18±0.28 VS. control 3.63±0.76）, 24weeks later（trail group 1.75±0.81Vs. control 2.98±0.46）. In addition, in the 4 follow-ups the PHN in the trail groups were significantly decrease compared with that of control group. Besides, side effect was not observed in both two groups. Conclusion The combination treatment of wIRA and Valacyclovir, Methylcobal amin and Gabapentin is superior to traditional pharmaceutical treatment.
出处
《中国实用神经疾病杂志》
2018年第2期203-205,共3页
Chinese Journal of Practical Nervous Diseases
基金
河南省科技攻关计划项目
编号:201503218
